Compare · ALHC vs ILMN
ALHC vs ILMN
Side-by-side comparison of Alignment Healthcare Inc. (ALHC) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALHC and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $33.97B, about 12.1x ALHC ($2.82B).
- Over the past year, ALHC is down 13.2% and ILMN is up 127.9% - ILMN leads by 141.1 points.
- ILMN has been more active in the news (11 items in the past 4 weeks vs 5 for ALHC).
- Both have 25 recent analyst ratings on file.
- Company
- Alignment Healthcare Inc.
- Illumina Inc.
- Price
- $13.60+1.19%
- $225.01+0.76%
- Market cap
- $2.82B
- $33.97B
- 1M return
- -27.14%
- +18.79%
- 1Y return
- -13.21%
- +127.94%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2000
- News (4w)
- 5
- 11
- Recent ratings
- 25
- 25
Alignment Healthcare Inc.
Alignment Healthcare, Inc. provides a consumer-centric platform that delivers customized health care to seniors in the United States. It offers medicare advantage plans and health plan options to its partners and patients with customized care and service; and preferred provider organization offerings. The company was founded in 2013 and is based in Orange, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ALHC
- Alignment Healthcare to Present in Baird 2026 Global Healthcare Conference and Attend Morgan Stanley 24th Annual Global Healthcare Conference
- President Maroney Dawn Christine sold $70,000 worth of shares (5,000 units at $14.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.54% to 917,313 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Alignment Healthcare Inc.
- Chief Executive Officer Kao John E sold $4,136,776 worth of shares (298,000 units at $13.88) as part of a pre-agreed trading plan (SEC Form 4)
- Alignment Healthcare downgraded by Raymond James with a new price target
- SEC Form 10-Q filed by Alignment Healthcare Inc.
- Alignment Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics
- President Maroney Dawn Christine exercised 152,068 shares at a strike of $9.06 and sold $3,687,990 worth of shares (177,068 units at $20.83) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 922,313 units (SEC Form 4)
- Chief Executive Officer Kao John E sold $5,919,361 worth of shares (298,000 units at $19.86) as part of a pre-agreed trading plan (SEC Form 4)
Latest ILMN
- Director Meister Keith A. sold $145,556,398 worth of shares (679,574 units at $214.19) (SEC Form 4)
- SVP, Strategy/Corp Development Wedel Christensen Jakob sold $197,840 worth of shares (1,033 units at $191.52), decreasing direct ownership by 7% to 14,023 units (SEC Form 4)
- SEC Form 8-K filed by Illumina Inc.
- Illumina Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 8-K filed by Illumina Inc.
- SEC Form 3 filed by new insider Coletti Julie Ann
- SEC Form FWP filed by Illumina Inc.
- Chief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)
- Illumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Director Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)